Article
Biochemistry & Molecular Biology
Tine L. Dohlmann, Anja B. Kuhlman, Thomas Morville, Maria Dahl, Magnus Asping, Patrick Orlando, Sonia Silvestri, Luca Tiano, Jorn W. Helge, Flemming Dela, Steen Larsen
Summary: This study investigated whether concurrent administration of CoQ10 with statins increases muscle CoQ10 levels and improves mitochondrial function, as well as whether changes in muscle CoQ10 levels correlate with changes in the intensity of myalgia. The results showed that CoQ10 supplementation had no effect on muscle CoQ10 levels or mitochondrial function, and individual changes in muscle CoQ10 levels were not correlated with changes in intensity of myalgia.
Review
Biochemistry & Molecular Biology
Giulia Maria Camerino, Nancy Tarantino, Ileana Canfora, Michela De Bellis, Olimpia Musumeci, Sabata Pierno
Summary: Statins are effective drugs for treating cardiovascular diseases, but can lead to skeletal muscle toxicity which needs risk assessment and study of new biomarkers. Identifying a marker of toxicity is important to prevent or to cure statin induced myopathy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Rhonda M. Cooper-DeHoff, Mikko Niemi, Laura B. Ramsey, Jasmine A. Luzum, E. Katriina Tarkiainen, Robert J. Straka, Li Gong, Sony Tuteja, Russell A. Wilke, Mia Wadelius, Eric A. Larson, Dan M. Roden, Teri E. Klein, Sook Wah Yee, Ronald M. Krauss, Richard M. Turner, Latha Palaniappan, Andrea Gaedigk, Kathleen M. Giacomini, Kelly E. Caudle, Deepak Voora
Summary: Statins are commonly prescribed medications that reduce cholesterol and prevent cardiovascular disease. However, statin-associated musculoskeletal symptoms can affect patient adherence and long-term effectiveness. Genetic variations in SLCO1B1, ABCG2, and CYP2C9 genes have been identified to impact the metabolism and adverse events of statins. This study summarizes the literature supporting these associations and provides therapeutic recommendations based on genotypes to improve the safety, adherence, and effectiveness of statin therapy.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
M. Casula, M. Gazzotti, F. Bonaiti, E. OImastroni, M. Arca, M. Averna, A. Zambon, A. L. Catapano
Summary: The PROSISA study found that 9.6% of dyslipidaemic patients reported statin-associated muscle symptoms (SAMS), with only one third of patients still reporting SAMS after dechallenge/rechallenge.
JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Pedro Engel Gonzalez, Mark A. Hlatky, JoAnn E. Manson, Julie E. Buring, I-Min Lee, Nancy R. Cook, Vadim Bubes, Neil J. Stone
Summary: This study found that female gender and younger age (50-64 years) were significant and independent predictors of higher rates of statin-associated muscle symptoms (SAMS).
AMERICAN HEART JOURNAL
(2022)
Article
Clinical Neurology
Wesley R. Cole, Catherine L. Tegeler, Y. Sammy Choi, Tyler E. Harris, Nora Rachels, Paula G. Bellini, Thaddeus J. Haight, Lee Gerdes, Charles H. Tegeler, Michael J. Roy
Summary: This study found that the use of Cereset Research(TM) Standard Operating Procedures (CR-SOP) auditory stimulation neurotechnology can improve symptoms after a concussion. However, linking the tones to brainwave activity did not reduce symptoms more than random tones.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2023)
Review
Biochemistry & Molecular Biology
Pierandrea Vinci, Emiliano Panizon, Letizia Maria Tosoni, Carla Cerrato, Federica Pellicori, Filippo Mearelli, Chiara Biasinutto, Nicola Fiotti, Filippo Giorgio Di Girolamo, Gianni Biolo
Summary: Hyperlipidemia is a major risk factor for cardiovascular morbidity and mortality, and statins are the first-choice therapy for dyslipidemias. However, patient compliance is poor and statin-associated muscle symptoms are the most common side effect leading to treatment discontinuation.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Rheumatology
Maheswari Muruganandam, Ahsan Iqbal, Eyerusalem B. Akpan, Anthony C. Dolomisiewicz, Yvonne M. Waters, N. Suzanne Emil, Sharon E. Nunez, Matthew K. McElwee, Frank X. O'Sullivan, Roderick A. Fields, Wilmer L. Sibbitt
Summary: This study compared the manifestations of immune-mediated necrotizing myopathy (IMNM) to idiopathic inflammatory myositis (IIM) in Native Americans. It found that IMNM patients were older and more likely to have diabetes, hyperlipidemia, and statin exposure. They also had significantly higher levels of creatine kinase and anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) antibodies, and a higher prevalence of necrotizing myopathy. However, they had shorter disease duration and fewer cutaneous or vascular manifestations compared to IIM patients.
Article
Pharmacology & Pharmacy
Trine Lauritzen, John Munkhaugen, Kari Peersen, Oscar Kristiansen, Elise Sverre, Shane D. Nebauer, Maja Villseth, Anders M. Andersen, Anja Camilla Svarstad, Elena Prunes Jensen, Stein Bergan, Einar Husebye, Nils Tore Vethe
Summary: Self-perceived statin-associated muscle symptoms (SAMS) are common but mostly not related to the drug itself. The study aimed to determine the correlation between atorvastatin metabolites in blood and skeletal muscle, and if genetic variants of statin transporters influence this relationship. Muscle symptoms were examined in patients with coronary disease during treatment with atorvastatin 40 mg/day and placebo. The study found strong correlations between muscle and blood plasma concentrations of atorvastatin metabolites, suggesting that blood measurements can reflect muscle tissue exposure. The relationship between atorvastatin metabolites in blood and SAMS warrants further investigation.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Physiology
Barrie Tan, Kok-Yong Chin
Summary: Myopathy is a common side effect of statins, and supplementation with geranylgeraniol has shown potential in reversing statin-associated muscle symptoms (SAMS).
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Gastroenterology & Hepatology
Babu Lal Meena, Sunil Taneja, Puneeta Tandon, Nancy Sahni, Raghuraman Soundararajan, Ujjwal Gorsi, Arka De, Nipun Verma, Madhumita Premkumar, Ajay Duseja, Radha K. Dhiman, Virendra Singh
Summary: This study found that a 6-month dietitian-supported home-based intensive outpatient nutrition therapy significantly improved frailty and sarcopenia in patients with decompensated cirrhosis. Adherent patients also showed improvement in liver disease scores and reduction in mortality.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Pharmacology & Pharmacy
Barbara S. Wiggins, James M. Backes, Daniel Hilleman
Summary: 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, known as statins, are considered the first-line pharmacologic therapy for reducing LDL-C. However, they can have possible adverse effects, with musculoskeletal problems being the most common side effect. Nonadherence to statin therapy can have a negative impact on patient care, thus understanding risk factors, diagnosis, and management is important for optimizing care.
Review
Pharmacology & Pharmacy
Natasha J. Petry, Jordan F. Baye, Samantha Frear, Kristen Jacobsen, Amanda Massmann, April Schultz, Joel Van Heukelom, Kurt Christensen
Summary: This article provides a historical background on statins and their associated pharmacogenomics, discusses the application of clinical decision support, and addresses future implications.
Article
Oncology
In Gab Jeong, Bumjin Lim, Sung-Cheol Yun, Ju Hyun Lim, Jun Hyuk Hong, Choung-Soo Kim
Summary: The study aimed to evaluate the efficacy of adjuvant atorvastatin in high-risk prostate cancer patients after radical prostatectomy. However, the results showed that 1-year adjuvant use of atorvastatin did not reduce the risk of disease recurrence compared to placebo in this patient population.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Mary M. McDermott, Lydia Bazzano, Charlotte A. Peterson, Robert Sufit, Luigi Ferrucci, Kathryn Domanchuk, Lihui Zhao, Tamar S. Polonsky, Dongxue Zhang, Donald Lloyd-Jones, Christiaan Leeuwenburgh, Jack M. Guralnik, Melina R. Kibbe, Kate Kosmac, Michael H. Criqui, Lu Tian
Summary: The study aimed to investigate whether telmisartan improves walking performance in patients with lower extremity PAD, but the results showed that telmisartan did not significantly improve walking distance at 6-month follow-up.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, John Gregson, Stuart J. Pocock, Christie M. Ballantyne
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2019)
Article
Medicine, General & Internal
Jamal S. Rana, Jennifer Y. Liu, Howard H. Moffet, Robert J. Sanchez, Irfan Khan, Andrew J. Karter
AMERICAN JOURNAL OF MEDICINE
(2020)
Letter
Cardiac & Cardiovascular Systems
Deepak L. Bhatt, Ph. Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Lixia Jiao, Jean-Claude Tardif, John Gregson, Stuart J. Pocock
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2019)
Article
Cardiac & Cardiovascular Systems
Irfan Khan, Eric D. Peterson, Christopher P. Cannon, Lauren E. Sedita, Jay M. Edelberg, Kausik K. Ray
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2020)
Letter
Cardiac & Cardiovascular Systems
Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Craig Granowitz, Jean-Claude Tardif, Cyrus Mehta, Rajat Mukherjee, Christie M. Ballantyne, Mina K. Chung
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Dylan L. Steen, Irfan Khan, Katherine Andrade, Alexandra Koumas, Robert P. Giugliano
Summary: Patients with acute coronary syndrome (ACS) remain at a very high risk of experiencing recurrent cardiovascular events, particularly early after discharge. Among different subgroups, patients without revascularization and with a Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention >= 4 had the highest 5-year event rate for the primary cardiovascular end point.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent Ethyl significantly reduces the risk of recurrent cardiovascular events in patients with elevated triglycerides and a history of prior percutaneous coronary intervention.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Senthil Selvaraj, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Rebecca A. Juliano, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne
Summary: This study aimed to investigate the treatment effects of icosapent ethyl in patients with heart failure (HF). The results showed that icosapent ethyl reduced triglyceride and hs-CRP levels in patients with HF, and had similar cardiovascular risk reduction effects.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Article
Cardiac & Cardiovascular Systems
Michael Miller, Deepak L. Bhatt, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne, Matthew Budoff, R. Preston Mason
Summary: The study found that the use of IPE can reduce the risk of cardiovascular disease in smokers to the level observed in non-smokers.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Michel Farnier, Raul D. Santos, Juan Cosin-Sales, Marat Ezhov, Jian Liu, Denis Granados, Serena Santoni, Irfan Khan, Alberico L. Catapano
Summary: According to the 2019 ESC/EAS guidelines, the use of statin, ezetimibe, and statin plus ezetimibe FDC treatment strategies can significantly reduce the incidence of major adverse cardiovascular events at the population level.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY
(2022)
Article
Computer Science, Artificial Intelligence
Paidamoyo Chapfuwa, Chenyang Tao, Chunyuan Li, Irfan Khan, Karen J. Chandross, Michael J. Pencina, Lawrence Carin, Ricardo Henao
Summary: Models for predicting the time of a future event are crucial for risk assessment. We propose neural time-to-event models that account for calibration and uncertainty while predicting accurate absolute event times.
IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS
(2023)
Article
Cardiac & Cardiovascular Systems
Brian Olshansky, Deepak L. L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. A. Brinton, Terry A. A. Jacobson, Steven B. B. Ketchum, Ralph T. T. Doyle Jr, Rebecca A. A. Juliano, Lixia Jiao, Peter R. R. Kowey, James A. A. Reiffel, Jean-Claude Tardif, Christie M. M. Ballantyne, Mina K. K. Chung
Summary: In the REDUCE-IT study, icosapent ethyl (IPE) reduced cardiovascular events but was associated with increased atrial fibrillation/atrial flutter (AF) hospitalization. The study analyzed the relationships between IPE and outcomes in patients with or without prior AF and with or without in-study AF hospitalization. Overall, in-study AF hospitalization rates were higher in patients with prior AF, especially in those randomized to IPE. Serious bleeding rates also trended higher in these patients. However, patients with prior AF or in-study AF hospitalization showed consistent risk reductions in cardiovascular events with IPE.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Pharmacology & Pharmacy
Peter W. F. Wilson, Terry A. Jacobson, Seth S. Martin, Elizabeth J. Jackson, N-Anh Le, Michael H. Davidson, Hubert W. Vesper, Ruth Frikke-Schmidt, Christie M. Ballantyne, Alan T. Remaley
Summary: The measurement of lipoproteins is crucial for managing patients with coronary heart disease and atherosclerotic cardiovascular disease. Guidelines for lipid measurements have evolved to optimize cardiovascular risk assessment and prevention. Screening with nonfasting lipids is acceptable, and the use of non-HDL-C and alternative methods for estimating LDL-C are recommended, especially for patients with specific lipid profiles. Harmonization of advanced lipid measurement methods and timely follow-up after changes in lipid treatment are also emphasized for better clinical outcomes.
JOURNAL OF CLINICAL LIPIDOLOGY
(2021)
Meeting Abstract
Cardiac & Cardiovascular Systems
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye F. Dolman, Cheng Zhang, William E. Boden, Adam P. Bress, Jordan B. King, Philippe G. Steg, Eliot A. Brinton, Terry A. Jacobson, Jean Claude Tardif, Christie M. Ballantyne, Paul Kolm
Correction
Hematology
Connie B. Newman, David Preiss, Jonathan A. Tobert, Terry A. Jacobson, Robert L. Page, Larry B. Goldstein, Clifford Chin, Lisa R. Tannock, Michael Miller, Geetha Raghuveer, P. Barton Duell, Eliot A. Brinton, Amy Pollak, Lynne T. Braun, Francine K. Welty
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2019)
